So-called weight-loss drugs are generating waves of hope and hype. Names such as Wegovy, Ozempic and Mounjaro fall breathlessly from the lips of social media influencers, bringing promise and possibility to the one billion people the World Health Organization says suffer from obesity.

Investors are already buying in, sending the market caps of Novo Nordisk and Eli Lilly soaring into the ranks of the world’s most valuable companies.

Are these obesity drugs a fat-fighting panacea? Could they make junk food cravings a thing of the past? What’s their sales potential in Asia? Can makers of salty snacks lean in to a potential shift in eating habits?

Bloomberg Intelligence healthcare analysts Michael Shah and Leslie Yang join hosts John Lee and Tom Corbett to discuss whether these so-called "wonder drugs" can live up to their hype.